Cellosaurus logo
expasy logo

Cellosaurus HCT 116_6244R (CVCL_C3GI)

[Text version]
Cell line name HCT 116_6244R
Synonyms H6244-R; H6244-R1; HCT116R_6244R
Accession CVCL_C3GI
Resource Identification Initiative To cite this cell line use: HCT 116_6244R (RRID:CVCL_C3GI)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244).
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Colon; UBERON=UBERON_0001155.
Sequence variations
  • Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
Disease Colon carcinoma (NCIt: C4910)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0291 (HCT 116)
Sex of cell Male
Age at sampling 48Y
Category Cancer cell line
Publications

PubMed=21447798; DOI=10.1126/scisignal.2001752
Little A.S., Balmanno K., Sale M.J., Newman S., Dry J.R., Hampson M., Edwards P.A.W., Smith P.D., Cook S.J.
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Sci. Signal. 4:Ra17.1-Ra17.15(2011)

PubMed=31048689; DOI=10.1038/s41467-019-09438-w
Sale M.J., Balmanno K., Saxena J., Ozono E., Wojdyla K., McIntyre R.E., Gilley R., Woroniuk A., Howarth K.D., Hughes G., Dry J.R., Arends M.J., Caro P., Oxley D., Ashton S., Adams D.J., Saez-Rodriguez J., Smith P.D., Cook S.J.
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance.
Nat. Commun. 10:2030.1-2030.22(2019)

Cross-references
Cell line databases/resources cancercelllines; CVCL_C3GI
Encyclopedic resources Wikidata; Q114311571
Gene expression databases GEO; GSM3591762
Entry history
Entry creation22-Sep-2022
Last entry update05-Oct-2023
Version number5